Characterization of trisulfide modification in antibodies

Analytical Biochemistry

Volumn 400, Issue 1, 2010, Pages 89-98

  Gu, Sheng ^a   Wen, Dingyi ^a   Weinreb, Paul H ^a   Sun, Yaping ^a   Zhang, Lihe ^a   Foley, Susan F ^a   Kshirsagar, Rashmi ^a   Evans, David ^a   Mi, Sha ^a   Meier, Werner ^a   Pepinsky, R Blake ^a  

^a BIOGEN   (United States)

Author keywords

Disulfide structure; Natural antibodies; Peptide mapping; Posttranslational modification; Recombinant antibodies; Trisulfides; Trisulfides in proteins

Indexed keywords

COVALENT BONDS; LEAD COMPOUNDS; MAPPING; PEPTIDES; RECOMBINANT PROTEINS; SULFUR COMPOUNDS;

DISULFIDE BONDS; IMMUNOGLOBULIN G; PEPTIDE MAPPING; POST-TRANSLATIONAL MODIFICATIONS; RECOMBINANT ANTIBODY; SULFUR ATOMS; TRISULFIDES;

ANTIBODIES;

DISULFIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1 B; SULFIDE; TRISULFIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL CULTURE; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DISULFIDE BOND; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR STABILITY; MOLECULAR WEIGHT; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; TANDEM MASS SPECTROMETRY;

EID: 77649120640     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.01.019     Document Type: Article

References (30)

1. Nieri P., Donadio E., Rossi S., Adinolfi B., and Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr. Med. Chem. 16 (2009) 753-779
2. Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24 (2006) 769-776
3. Liu H., Gaza-Bulseco G., Faldu D., Chumsae C., and Sun J. Heterogeneity of monoclonal antibodies. J. Pharm. Sci. 97 (2008) 2426-2447
4. Jenkins N., Murphy L., and Tyther R. Post-translational modifications of recombinant proteins: Significance for biopharmaceuticals. Mol. Biotechnol. 39 (2008) 113-118
5. Walsh C. Posttranslational Modification of Proteins: Expanding Nature's Inventory (2005), Roberts and Company Publisher, Greenwood Village, CO
6. Barnes C.A.S., and Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom. Rev. 26 (2007) 370-388
7. Zhang Z.Q., Pan H., and Chen X.Y. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom. Rev. 28 (2009) 147-176
8. Glockshuber R., Schmidt T., and Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 31 (1992) 1270-1279
9. Glocker M.O., Arbogast B., and Deinzer M.L. Characterization of disulfide linkages and disulfide bond scrambling in recombinant human macrophage colony-stimulating factor by fast atom bombardment mass spectrometry of enzymatic digests. J. Am. Soc. Mass Spectrom. 6 (1995) 638-643
10. Gallogly M.M., and Mieyal J.J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol. 7 (2007) 381-391
11. Banks D.D., Gadgil H.S., Pipes G.D., Bondarenko P.V., Hobbs V., Scavezze J.L., Kim J., Jiang X.R., Mukku V., and Dillon T.M. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J. Pharm. Sci. 97 (2008) 775-790
12. Jespersen A.M., Christensen T., Klausen N.K., Nielsen F., and Sorensen H.H. Characterisation of a trisulphide derivative of biosynthetic human growth hormone produced in Escherichia coli. Eur. J. Biochem. 219 (1994) 365-373
13. Andersson C., Edlund P.O., Gellerfors P., Hansson Y., Holmberg E., Hult C., Johansson S., Kordel J., Lundin R., Mendel-Hartvig I.B., Noren B., Wehler T., Widmalm G., and Ohman J. Isolation and characterization of a trisulfide variant of recombinant human growth hormone formed during expression in Escherichia coli. Int. J. Pept. Protein Res. 47 (1996) 311-321
14. Canova-Davis E., Baldonado I.P., Chloupek R.C., Ling V.T., Gehant R., Olson K., and Gillece-Castro B.L. Confirmation by mass spectrometry of a trisulfide variant in methionyl human growth hormone biosynthesized in Escherichia coli. Anal. Chem. 68 (1996) 4044-4051
15. Breton J., Avanzi N., Valsasina B., Sgarella L., La Fiura A., Breme U., Orsini G., Wenisch E., and Righetti P.G. Detection of traces of a trisulphide derivative in the preparation of a recombinant truncated interleukin-6 mutein. J. Chromatogr. A 709 (1995) 135-146
16. Okado-Matsumoto A., Guan Z., and Fridovich I. Modification of cysteine 111 in human Cu,Zn-superoxide dismutase. Free Radic. Biol. Med. 41 (2006) 1837-1846
17. Thomsen M.K., Hansen B.S., Nilsson P., Nowak J., Johansen P.B., Thomsen P.D., and Christiansen J. Pharmacological characterization of a biosynthetic trisulfide-containing hydrophobic derivative of human growth hormone: comparison with standard 22 K growth hormone. Pharmacol. Toxicol. 74 (1994) 351-358
18. B. Hemmendorff, A. Castan, A. Persson, Method for the production of recombinant peptides with a low amount of trisulfides, U.S. Patent 7232,894 B1, 2007.
19. Pristatsky P., Cohen S.L., Krantz D., Acevedo J., Ionescu R., and Vlasak J. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Anal. Chem. 81 (2009) 6148-6155
20. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., and Wittrup K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. USA 105 (2008) 20167-20172
21. Wen D., Corina K., Chow E.P., Miller S., Janmey P.A., and Pepinsky R.B. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35 (1996) 9700-9709
22. 2S biogenesis by human cystathionine γ-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J. Biol. Chem. 284 (2009) 11601-11612
23. Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids 26 (2004) 243-254
24. 2S biogenesis via alternative trans-sulfuration reactions. J. Biol. Chem. 284 (2009) 22457-22466
25. Stipanuk M.H., and Beck P.W. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem. J. 206 (1982) 267-277
26. 2S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H474-H480
27. Goodwin L.R., Francom D., Dieken F.P., Taylor J.D., Warenycia M.W., Reiffenstein R.J., and Dowling G. Determination of sulfide in brain tissue by gas dialysis/ion chromatography: postmortem studies and two case reports. J. Anal. Toxicol. 13 (1989) 105-109
28. ATP channel opener. EMBO J. 20 (2001) 6008-6016
29. Liu Y.D., Chen X., Enk J.Z., Plant M., Dillon T.M., and Flynn G.C. Human IgG2 antibody disulfide rearrangement in vivo. J. Biol. Chem. 283 (2008) 29266-29272
30. Labrijn A.F., Buijsse A.O., van den Bremer E.T., Verwilligen A.Y., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G., and Parren P.W. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27 (2009) 767-771